Environmental, social and corporate governance (ESG) report
catalogue
03 / about this report
04 / Chairman’s speech
05 / about Shenzhen New Industries Biomedical Engineering Co.Ltd(300832)
2006 / 2021 key performance and honors
01 02
Corporate governance and product responsibility
09 / 1.1 corporate governance 16 / 2.1 strict control of product quality 09 / 1.1.1 strengthening corporate governance 16 / 2.1.1 quality management system 10 / 1.1.2 safeguarding the rights and interests of investors 18 / 2.1.2 quality management culture 11 / 1.2 ESG management 19 / 2.2 adhering to innovative R & D 11 / 1.2.1 Stakeholder communication 19 / 2.2.1 scientific and technological innovation system 12 / 1.2.2 substantive issues 19 / 2.2.2 ensuring R & D strength 13 / 1.3 compliant operation
13 / 1.3.1 strengthening risk control
14 / 1.3.2 strict adherence to business ethics
14 / 1.3.3 protecting information security
03 04 05
Employee responsibility environmental responsibility social responsibility
28 / 3.1 compliance and equal employment 35 / 4.1 improve resource efficiency 42 / 5.1 guarantee customer service 35 / 4.1.1 use of water resources 44 / 5.2 promote responsible procurement 28 / 3.2 talent attraction and retention 36 / 4.1.2 use of office supplies 46 / 5.3 help industry development 28 / 3.2.1 guarantee salary and welfare 4 7 / 5.4 practice public welfare activities 30 / 3.2.2 diversified promotion and development 36 / 4.2 strictly control pollution emissions
30 / 3.2.3 employee ability training 36 / 4.2.1 wastewater and waste gas management
32 / 3.2.4 work life balance 36 / 4.2.2 waste management
33 / 3.3 occupational health and safety 38 / 4.3 addressing climate change
38 / 4.3.1 identifying risks and opportunities
39 / 4.3.2 promoting low-carbon development
49 / future outlook
50 / appendix
50 / KPI table
53 / gri index table
About this report
The report states that this report is the first environmental social & Governance (hereinafter referred to as “ESG”) report issued by Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) to comprehensively show the company’s performance in ESG and its unremitting efforts for sustainable development.
Scope of the report the organizational scope of the report is Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) . The time range of this report is from January 1, 2021 to December 31, 2021. Some contents beyond the above scope will be explained in the text.
Description of appellation for ease of expression, Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) in this report is represented by ” Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) “, “company” and “we”.
Data description the data in this report are from the official documents and statistical reports of Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) . The company promises that there are no false records, misleading statements or major omissions in the contents of this report.
This report is prepared according to the core program of gri standards issued by the global sustainable development standards committee (gssb).
You can publish the report on cninfo (www.cn. Info. Com. CN), the information disclosure website designated by Shenzhen Stock Exchange Or the official website of Shenzhen Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) Biomedical Engineering Co., Ltd. (www.snibe. Com.) Check and download the electronic version of this report on the website for more company information. If you have any questions or suggestions about the report, please send an email to [email protected]. Or call 075586540062.
Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) 03
Chairman’s speech
2021 is a year of orderly restart after the covid-19 pneumonia epidemic pressed the pause button. It is the first year to march towards the goal of “the second century” and the 26th year for Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) focusing on the field of in vitro diagnosis. This year, the new industry operated steadily, achieved a good performance of 20000 + installed units worldwide, provided services to medical terminals in 147 countries and regions, and made great progress in the in vitro diagnosis industry.
Lean manufacturing, dedicated service, green and harmonious coexistence
Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) adhering to the enterprise spirit of “defending product quality as defending life” Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) adhering to the concept of sustainable development, we actively respond to the national spirit and make good products with our heart. We are committed to the “carbon emission control” of the company’s R & D and production processes, and continuously improve the quality of our products. We recognize the risks and opportunities brought about by climate change, do not enhance our competitive advantage, obtain a number of quality management including ISO 9001, continuously improve the efficiency of energy and resource use, strictly manage the emission of pollutants, and save system certification. We adhere to R & D innovation, realize the transformation of a number of R & D achievements, and implement the concept of reducing carbon. At present, the company has obtained 189 China National Chemical Engineering Co.Ltd(601117) luminescent reagent registration certificates (covering 145 chemiluminescent reagent projects), 61 biochemical reagent registration certificates, and 162 chemiluminescent reagents sold worldwide, including 155 chemiluminescent reagents and 61 biochemical reagents that have been admitted to the EU. We listen attentively to the needs of customers at home and abroad, constantly improve service quality and customer satisfaction. In the same boat, spring blossoms and autumn fruits, Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) will promote social health and industry development as its own responsibility, and actively undertake corporate social responsibility. During the outbreak of covid-19 epidemic, we assisted all walks of life at home and abroad and donated covid-19 virus detection reagents and other people-oriented epidemic prevention materials, so as to add scientific and technological strength to epidemic prevention and control. At the same time, we hold off campus science popularization classes to enhance public medical and health awareness.
In the past year, Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) concentrated. We pay attention to the growth and development of every employee and are committed to creating an equal, inclusive, warm and harmonious working environment for employees Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) continuously improve the employee compensation and welfare system and provide a diversified future, Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) will continue to pursue excellence, continue to improve the development opportunities, rich learning resources and perfect development path of sustainable development management, so that employees can grow together with the enterprise with the mission of continuously creating value for human life and health. This year, Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) won the “Master Award for the most influential employee to forge ahead in the future”.
About Shenzhen New Industries Biomedical Engineering Co.Ltd(300832)
Company profile Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) was established in 1995. It is a national high-tech enterprise specializing in the R & D, production, sales and service of in vitro diagnostic products.
Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) bio is the first company in China to hold the patent of “immunomagnetic microsphere” and use it as the key separation material of chemiluminescence system. It is also the first company in China to hold the patent of “synthetic small molecular organic compound Abei” and use it instead of traditional enzyme as luminescence marker, At the same time, it is also the first company in China to apply the above patented technology, obtain the Chinese registration certificate and realize the mass production of fully automatic direct chemiluminescence immunoassay instruments and supporting reagents. The company’s R & D achievements have filled the gap in the field of in vitro diagnosis in China,
